|
Allele Symbol Allele Name Allele ID |
Rragcem1Efe endonuclease-mediated mutation 1, Alejo Efeyan MGI:6874615 |
||||||||||||||||
| Summary |
3 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• only 6.2% of homozygotes are recovered at E13.5, indicating partial embryonic lethality
|
|
• no viable homozygotes are produced from breeding heterozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• heterozygotes are obtained at normal Mendelian ratios and exhibit normal longevity and age-dependent health decline with no major alterations in age-related pathologies
|
|
• after intraperitoneal injection of sheep red blood cells (SRBCs), mice show a two-thirds reduction in the number of GC B cells in spleen; the % of IgG1+ cells in GC B cells is also decreased in spleen
• however, GC B cell proliferation is normal, as measured by EdU incorporation in spleen
|
|
• after intraperitoneal injection of SRBCs, plasma cell (PC) number is reduced; the % of IgG1+ cells in PCs is also decreased in spleen
|
|
• after intraperitoneal injection of SRBCs, mice show a two-thirds reduction in total GC area / spleen area
• however, the GC dark zone/light zone ratio is not significantly altered
|
|
• after immunization with SRBCs, naive B cells, germinal center (GC) B cells, and plasma cells (PCs) display a significant reduction in mTORC1 activity, as shown by intracellular staining of S235/236-phospho-S6
|
|
• ex vivo activation of isolated naive B cells with anti-CD40 plus interleukin-4 (IL4) results in decreased class switch recombination to IgG1
|
|
• B cells exhibit a cell-intrinsic inability to become activated upon immunization with SRBCs
|
|
• activation of isolated naive B cells with anti-CD40 plus IL4 results in decreased in vitro B cell proliferation, as measured by decay of carboxyfluorescein succinimidyl ester (CFSE)
|
|
• 10 days after immunization with SRBCs, serum titers of IgG1 antibodies are decreased
|
|
• 10 days after immunization with SRBCs, serum titers of IgM antibodies are decreased
|
|
• heterozygotes show a B-cell-intrinsic impaired humoral response in vitro and in vivo
|
| N |
• at 2-3-months of age, lymphoid and myeloid populations are present at normal frequencies in blood and spleen; normal numbers of stem cells and lymphoid and myeloid progenitors are found in bone marrow; subpopulations of splenic B cells (marginal zone, transitional, and follicular B cells) remain unaffected
|
|
• after intraperitoneal injection of sheep red blood cells (SRBCs), mice show a two-thirds reduction in the number of GC B cells in spleen; the % of IgG1+ cells in GC B cells is also decreased in spleen
• however, GC B cell proliferation is normal, as measured by EdU incorporation in spleen
|
|
• after intraperitoneal injection of SRBCs, plasma cell (PC) number is reduced; the % of IgG1+ cells in PCs is also decreased in spleen
|
|
• after intraperitoneal injection of SRBCs, mice show a two-thirds reduction in total GC area / spleen area
• however, the GC dark zone/light zone ratio is not significantly altered
|
|
• after immunization with SRBCs, naive B cells, germinal center (GC) B cells, and plasma cells (PCs) display a significant reduction in mTORC1 activity, as shown by intracellular staining of S235/236-phospho-S6
|
|
• ex vivo activation of isolated naive B cells with anti-CD40 plus interleukin-4 (IL4) results in decreased class switch recombination to IgG1
|
|
• B cells exhibit a cell-intrinsic inability to become activated upon immunization with SRBCs
|
|
• activation of isolated naive B cells with anti-CD40 plus IL4 results in decreased in vitro B cell proliferation, as measured by decay of carboxyfluorescein succinimidyl ester (CFSE)
|
|
• 10 days after immunization with SRBCs, serum titers of IgG1 antibodies are decreased
|
|
• 10 days after immunization with SRBCs, serum titers of IgM antibodies are decreased
|
|
• activation of isolated naive B cells with anti-CD40 plus IL4 results in decreased in vitro B cell proliferation, as measured by decay of carboxyfluorescein succinimidyl ester (CFSE)
|
|
• after amino acid starvation followed by acute stimulation with amino acids, mouse embryonic fibroblasts (MEFs) derived from heterozygous females show a mild but consistent reduction in mTORC1 activity
|
|
• after amino acid starvation followed by acute stimulation with amino acids, primary hepatocytes from heterozygous females show a mild but consistent reduction in mTORC1 activity
|
| N |
• 7- to -8-week-old heterozygotes are macroscopically normal with no significant differences in body weight or in liver, WAT, lung, heart, pancreas and spleen weight relative to wild-type controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice show a significant delay in follicular lymphoma (FL) and high-grade lymphoma development relative to mice carrying the transgene on a wild-type background; all tumors display pathognomonic features of FL and a similar Ki67 proliferative index in spleen
• although mice show a reduced incidence of FL when sacrificed at 250 days, the incidence, grade, tumor burden and PD1+ microenvironment of FL at euthanasia are similar to those in mice carrying the transgene on a wild-type background
|
|
• both unimmunized and SRBC-immunized mice exhibit a lower number of GC B cells in spleen than control mice carrying the transgene on a wild-type background
|
|
• mice exhibit a smaller spontaneous GC formation in spleen than mice carrying the transgene on a wild-type background
|
|
• mice exhibit delayed development of autoimmune glomerulonephritis with a lower number of IgG1+ deposits in the kidney than mice carrying the transgene on a wild-type background
|
|
• both unimmunized and SRBC-immunized mice exhibit a lower number of GC B cells in spleen than control mice carrying the transgene on a wild-type background
|
|
• mice exhibit a smaller spontaneous GC formation in spleen than mice carrying the transgene on a wild-type background
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 05/07/2024 MGI 6.23 |
|
|
|
||
Analysis Tools